Protagonist Therapeutics Inc
PTGX50.690USD
+0.480+0.96%
Close 07/02, 16:00（ET）Quotes delayed by 15 min
3.14BMarket Cap
10.01P/E TTM
More Details of Protagonist Therapeutics Inc Company
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Company Info
Ticker SymbolPTGX
Company nameProtagonist Therapeutics Inc
IPO dateAug 11, 2016
Founded at2006
CEODr. Dinesh V. Patel, Ph.D.
Number of employees126
Security typeOrdinary Share
Fiscal year-endAug 11
Address7707 Gateway Blvd Ste 140
CityNEWARK
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94560-1160
Phone15104740170
Websitehttps://www.protagonist-inc.com/
Ticker SymbolPTGX
IPO dateAug 11, 2016
Founded at2006
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
357.08K
-0.38%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
--
-100.00%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Mr. Corey Davis, Ph.D.
Mr. Corey Davis, Ph.D.
IR Contact Officer
IR Contact Officer
--
--
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
357.08K
-0.38%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.87%
Farallon Capital Management, L.L.C.
9.85%
RTW Investments L.P.
9.23%
The Vanguard Group, Inc.
6.88%
Deep Track Capital LP
5.24%
Other
54.92%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.87%
Farallon Capital Management, L.L.C.
9.85%
RTW Investments L.P.
9.23%
The Vanguard Group, Inc.
6.88%
Deep Track Capital LP
5.24%
Other
54.92%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
33.20%
Investment Advisor
33.04%
Hedge Fund
30.09%
Research Firm
4.41%
Venture Capital
4.17%
Private Equity
1.86%
Individual Investor
1.10%
Pension Fund
1.03%
Bank and Trust
0.35%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
522
67.76M
109.32%
-9.35M
2025Q1
541
67.25M
108.51%
-8.96M
2024Q4
503
65.58M
106.87%
-12.21M
2024Q3
480
64.24M
108.98%
-11.36M
2024Q2
419
61.14M
104.21%
-15.61M
2024Q1
412
61.98M
106.36%
-12.46M
2023Q4
402
59.53M
103.21%
-16.02M
2023Q3
400
59.06M
102.70%
-14.36M
2023Q2
411
59.30M
103.68%
-17.88M
2023Q1
397
55.80M
108.46%
-12.55M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
8.60M
13.87%
-162.95K
-1.86%
Mar 31, 2025
Farallon Capital Management, L.L.C.
6.11M
9.85%
+177.00K
+2.98%
Mar 31, 2025
RTW Investments L.P.
5.72M
9.23%
+220.87K
+4.02%
Mar 31, 2025
The Vanguard Group, Inc.
4.27M
6.88%
+57.18K
+1.36%
Mar 31, 2025
Deep Track Capital LP
3.25M
5.24%
+250.00K
+8.33%
Apr 03, 2025
BVF Partners L.P.
3.21M
5.18%
+636.03K
+24.70%
Jun 09, 2025
State Street Global Advisors (US)
2.71M
4.37%
-624.44K
-18.75%
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.45M
3.95%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.42M
2.3%
+46.50K
+3.38%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.27M
2.06%
-71.66K
-5.33%
Mar 31, 2025
View more
Related ETFs
Updated: 23 hours ago
Updated: 23 hours ago
Name
Proportion
Invesco Biotechnology & Genome ETF
3.93%
Invesco Dorsey Wright Healthcare Momentum ETF
3.07%
ALPS Medical Breakthroughs ETF
2.64%
Invesco S&P SmallCap Health Care ETF
2.02%
Invesco S&P SmallCap 600 Pure Growth ETF
1.86%
ETC 6 Meridian Small Cap Equity ETF
1.43%
Virtus LifeSci Biotech Clinical Trials ETF
1.35%
Inspire Fidelis Multi Factor ETF
0.94%
Invesco S&P SmallCap Quality ETF
0.91%
Cambria Value and Momentum ETF
0.84%
View more
Invesco Biotechnology & Genome ETF
Proportion3.93%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion3.07%
ALPS Medical Breakthroughs ETF
Proportion2.64%
Invesco S&P SmallCap Health Care ETF
Proportion2.02%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.86%
ETC 6 Meridian Small Cap Equity ETF
Proportion1.43%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.35%
Inspire Fidelis Multi Factor ETF
Proportion0.94%
Invesco S&P SmallCap Quality ETF
Proportion0.91%
Cambria Value and Momentum ETF
Proportion0.84%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
